VERTEX PHARMACEUTICALS INC / MA — Director's Dealing 2019

Aug 6, 2019

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: VERTEX PHARMACEUTICALS INC / MA (VRTX)
CIK: 0000875320
Period of Report: 2019-08-02

Reporting Person: Arbuckle Stuart A (EVP\Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-02	Common Stock	M	2155	$91.05	Acquired	34395	Direct
2019-08-02	Common Stock	S	2155	$177.78	Disposed	32240	Direct
2019-08-05	Common Stock	M	1553	$86.52	Acquired	33793	Direct
2019-08-05	Common Stock	S	1553	$176.44	Disposed	32240	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2019-08-02	Stock Option (Right to Buy)	$91.05	M	2155	Acquired	2026-02-01	Common Stock (2155)	Direct
2019-08-05	Stock Option (Right to Buy)	$86.52	M	1553	Acquired	2027-02-02	Common Stock (1553)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	140	Indirect

Footnotes

F1: Transaction made pursuant to Mr. Arbuckle's company approved trading plan under Rule 10b5-1.

F2: The option vests in 16 quarterly installments from 2/2/2016.

F3: The option vests in 16 quarterly installments from 2/3/2017.